FernandaDe PinhoSilveiraMD

Infectious Disease • Pittsburgh, PA

Professor of Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Silveira is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Silveira's full profile

Already have an account?

Office
3601 Fifth Avenue
# 700
Pittsburgh, PA 15213
Phone+1 412-647-7228

Fax+1 412-647-3162

Education & Training

UPMC Medical EducationFellowship, Infectious Disease, 2003 - 2005
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2000 - 2003
Faculdade de Medicina da Universidade Federal do Rio de JaneiroClass of 1998

Certifications & Licensure

PA State Medical License 2003 - 2026
American Board of Internal Medicine Infectious Disease

Clinical Trials

Invasive Fungal Infections Surveillance Initiative Start of enrollment: 2005 Aug 01
Completed
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) Start of enrollment: 2008 Jun 01
Completed
Not Applicable
Infectious Outcomes Following Pancreas Transplantation Start of enrollment: 2006 Apr 01
Completed
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation Start of enrollment: 2007 Jan 01
Withdrawn
Not Applicable
Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1) Start of enrollment: 2009 Oct 15
Completed
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Start of enrollment: 2012 Oct 29
Completed
Phase 4
Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients Start of enrollment: 2015 Jul 01
Terminated
Letermovir for CMV Prevention After Lung Transplantation Start of enrollment: 2021 Dec 06
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Vaccine effectiveness against influenza-associated hospitalizations in adults with liver disease, 2015-2020: US Hospitalized Adult Influenza Vaccine Effectiveness Netw...
Po-Han Huang, Mary Patricia Nowalk, Richard K Zimmerman, Samantha M Olson, H Keipp Talbot
Human Vaccines & Immunotherapeutics. 2025-12-01
Evolving Impact of COVID-19 on Intestinal Transplant Recipients: A Single-Center Experience.
Colin Powers, Brielle Corrente, Jennifer Joyce, William Stein, Shelly Polydor
Clinical Transplantation. 2025-01-01
Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018.
Kailey Hughes Kramer, Richard K Zimmerman, Catherine L Haggerty, G K Balasubramani, Mary Patricia Nowalk
Human Vaccines & Immunotherapeutics. 2024-12-31

Press Mentions

$Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients with Cytomegalovirus (CMV) Infection (Refractory, with or Without Resistance)$
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients with Cytomegalovirus (CMV) Infection (Refractory, with or Without Resistance)December 7th, 2021
More Organs Available for Transplant Because of Opioid EpidemicApril 18th, 2018